Dementia, Lewy Body (DLB)

Categories: Genetic diseases, Mental diseases, Rare diseases

Aliases & Classifications for Dementia, Lewy Body

MalaCards integrated aliases for Dementia, Lewy Body:

Name: Dementia, Lewy Body 56 25 73 13
Lewy Body Dementia 56 12 52 25 53 73 36 29 6 42 15 39 17
Lewy Body Disease 12 52 25 54 43 71
Diffuse Lewy Body Disease 56 12 52 25 73
Dementia with Lewy Bodies 12 74 25 53 15
Dlb 56 52 25 73
Autosomal Dominant Diffuse Lewy Body Disease 52 71
Diffuse Lewy Body Disease with Gaze Palsy 73
Lewy Body Variant of Alzheimer Disease 73
Dementia, Lewy Body, Susceptibility to 6
Lewy Body Dementia, Susceptibility to 56
Senile Dementia of the Lewy Body Type 12
Dementia of the Lewy Body Type 25
Lewy Body Type Senile Dementia 73
Dysphasic Dementia Hereditary 73
Cortical Lewy Body Disease 73
Lewy Bodies 29
Lbd 25



autosomal dominant

onset in the sixth or seventh decades
phenotypic overlap with parkinson disease
allelic disorder to parkinson disease-1 (park1, )


dementia, lewy body:
Inheritance autosomal dominant inheritance


External Ids:

Disease Ontology 12 DOID:12217
OMIM 56 127750
KEGG 36 H00066
ICD9CM 34 331.82
MeSH 43 D020961
NCIt 49 C84826
SNOMED-CT 67 80098002
ICD10 32 G31.83
UMLS 71 C0752347 C2931906

Summaries for Dementia, Lewy Body

MedlinePlus : 42 What is Lewy body dementia (LBD)? Lewy body dementia (LBD) is one of the most common types of dementia in older adults. Dementia is a loss of mental functions that is severe enough to affect your daily life and activities. These functions include Memory Language skills Visual perception (your ability to make sense of what you see) Problem solving Trouble with everyday tasks The ability to focus and pay attention What are the types of Lewy body dementia (LBD)? There are two types of LBD: dementia with Lewy bodies and Parkinson's disease dementia. Both types cause the same changes in the brain. And, over time, they can cause similar symptoms. The main difference is in when the cognitive (thinking) and movement symptoms start. Dementia with Lewy bodies causes problems with thinking ability that seem similar to Alzheimer's disease. Later, it also causes other symptoms, such as movement symptoms, visual hallucinations, and certain sleep disorders. It also causes more trouble with mental activities than with memory. Parkinson's disease dementia starts as a movement disorder. It first causes the symptoms of Parkinson's disease: slowed movement, muscle stiffness, tremor, and a shuffling walk. Later on, it causes dementia. What causes Lewy body dementia (LBD)? LBD happens when Lewy bodies build up in parts of the brain that control memory, thinking, and movement. Lewy bodies are abnormal deposits of a protein called alpha-synuclein. Researchers don't know exactly why these deposits form. But they do know that other diseases, such as Parkinson's disease, also involve a build-up of that protein. Who is at risk for Lewy body dementia (LBD)? The biggest risk factor for LBD is age; most people who get it are over age 50. People who have a family history of LBD are also at higher risk. What are the symptoms of Lewy body dementia (LBD)? LBD is a progressive disease. This means that the symptoms start slowly and get worse over time. The most common symptoms include changes in cognition, movement, sleep, and behavior: Dementia, which is a loss of mental functions that is severe enough to affect your daily life and activities Changes in concentration, attention, alertness, and wakefulness. These changes usually happen from day to day. But sometimes they can also happen throughout the same day. Visual hallucinations, which means seeing things that are not there Problems with movement and posture, including slowness of movement, difficulty walking, and muscle stiffness. These are called parkinsonian motor symptoms. REM sleep behavior disorder, a condition in which a person seems to act out dreams. It may include vivid dreaming, talking in one's sleep, violent movements, or falling out of bed. This may be the earliest symptom of LBD in some people. It can appear several years before any other LBD symptoms. Changes in behavior and mood, such as depression, anxiety, and apathy (a lack of interest in normal daily activities or events) In the early stages of LBD, symptoms can be mild, and people can function fairly normally. As the disease gets worse, people with LBD need more help due to problems with thinking and movement. In the later stages of the disease, they often cannot care for themselves. How is Lewy body dementia (LBD) diagnosed? There isn't one test that can diagnose LBD. It is important to see an experienced doctor to get a diagnosis. This would usually be specialist such as a neurologist. The doctor will Do a medical history, including taking a detailed account of the symptoms. The doctor will talk to both the patient and caregivers. Do physical and neurological exams Do tests to rule out other conditions that could cause similar symptoms. These could include blood tests and brain imaging tests. Do neuropsychological tests to evaluate memory and other cognitive functions LBD can be hard to diagnose, because Parkinson's disease and Alzheimer's disease cause similar symptoms. Scientists think that Lewy body disease might be related to these diseases, or that they sometimes happen together. It's also important to know which type of LBD a person has, so the doctor can treat that type's particular symptoms. It also helps the doctor understand how the disease will affect the person over time. The doctor makes a diagnosis based on when certain symptoms start: If cognitive symptoms start within a year of movement problems, the diagnosis is dementia with Lewy bodies If cognitive problems start more than a year after the movement problems, the diagnosis is Parkinson's disease dementia What are the treatments for Lewy body dementia (LBD)? There is no cure for LBD, but treatments can help with the symptoms: Medicines may help with some of the cognitive, movement, and psychiatric symptoms Physical therapy can help with movement problems Occupational therapy may help find ways to more easily do everyday activities Speech therapy may help with swallowing difficulties and trouble speaking loudly and clearly Mental health counseling can help people with LBD and their families learn how to manage difficult emotions and behaviors. It can also help them plan for the future. Music or art therapy may reduce anxiety and improve well-being Support groups can also be helpful for people with LBD and their caregivers. Support groups can give emotional and social support. They are also a place where people can share tips about how to deal with day-to-day challenges. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Dementia, Lewy Body, also known as lewy body dementia, is related to parkinson disease 3, autosomal dominant and perry syndrome, and has symptoms including seizures, tremor and back pain. An important gene associated with Dementia, Lewy Body is SNCA (Synuclein Alpha), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Circadian entrainment. The drugs Rotigotine and Modafinil have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are dementia and visual hallucinations

Disease Ontology : 12 A dementia that is characterized by the development of abnormal proteinaceous (alpha-synuclein) cytoplasmic inclusions, called Lewy bodies, throughout the brain that results in progressive decline in mental abilities.

Genetics Home Reference : 25 Dementia with Lewy bodies is a nervous system disorder characterized by a decline in intellectual function (dementia), a group of movement problems known as parkinsonism, visual hallucinations, sudden changes (fluctuations) in behavior and intellectual ability, and acting out dreams while asleep (REM sleep behavior disorder). This condition typically affects older adults, most often developing between ages 50 and 85. The life expectancy of individuals with dementia with Lewy bodies varies; people typically survive about 5 to 7 years after they are diagnosed. REM sleep behavior disorder may be the first sign of dementia with Lewy bodies. It can occur years before other symptoms appear. Individuals with REM sleep behavior disorder act out their dreams, talking and moving in their sleep when they should be still. This behavior becomes less pronounced as dementia with Lewy bodies worsens and additional features develop. Dementia is often the second major feature to develop in dementia with Lewy bodies. Initially, this intellectual decline may be mild or seem to come and go. In this condition, dementia often leads to impaired ability to perform visual-spatial tasks such as assembling puzzles. Affected individuals may also have poor problem-solving skills (executive functioning), speech difficulties, and reduced inhibitions. Problems with memory typically do not occur until later. Most people with dementia with Lewy bodies experience visual hallucinations, which often involve people or animals. Fluctuations in behavior and thought processes (cognition) include sudden changes in attention, unintelligible speech, and brief episodes of altered consciousness that may appear as staring spells. Parkinsonism is usually the last major feature to develop in people with dementia with Lewy bodies, although it can appear earlier in some individuals. The movement problems typically include tremors, rigidity, unusually slow movement (bradykinesia), and impaired balance and coordination (postural instability). Affected individuals may require walking aids or wheelchair assistance over time. Individuals with dementia with Lewy bodies may also experience a sharp drop in blood pressure upon standing (orthostatic hypotension), fainting episodes (syncope), reduced sense of smell, increased saliva production and drooling, difficulty controlling the flow of urine (incontinence), or constipation.

NIH Rare Diseases : 52 Lewy body dementia is one of the most common forms of progressive dementia . People affected by this condition may experience a variety of symptoms such as changes in alertness and attention; hallucinations; problems with movement and posture; muscle stiffness; confusion; and/or memory loss. Although the exact cause of Lewy body dementia is poorly understood, symptoms are thought to result when clumps of a protein called alpha-synuclein ("Lewy bodies") accumulate in the brain. Lewy body dementia usually occurs sporadically in people with no family history of the condition. Rarely, more than one family member may be affected. There is currently no cure for Lewy body dementia; however, medications may be available to help manage the associated symptoms.

OMIM : 56 Dementia with Lewy bodies (DLB) is a neurodegenerative disorder clinically characterized by dementia and parkinsonism, often with fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Pathologically, Lewy bodies are present in a pattern more widespread than usually observed in Parkinson disease (see PD; 168600). Alzheimer disease (AD; 104300)-associated pathology and spongiform changes may also be seen (McKeith et al., 1996; Mizutani, 2000; McKeith et al., 2005). (127750)

NINDS : 53 Dementia with Lewy bodies (DLB) is one of the most common types of progressive dementia. The central features of DLB include progressive cognitive decline, “fluctuations” in alertness and attention, visual hallucinations, and parkinsonian motor symptoms, such as slowness of movement, difficulty walking, or rigidity.  People may also suffer from depression.  The symptoms of DLB are caused by the build-up of Lewy bodies – accumulated bits of alpha-synuclein protein -- inside the nuclei of neurons in areas of the brain that control particular aspects of memory and motor control.  Researchers don’t know exactly why alpha-synuclein accumulates into Lewy bodies or how Lewy bodies cause the symptoms of DLB, but they do know that alpha-synuclein accumulation is also linked to Parkinson's disease, multiple system atrophy, and several other disorders, which are referred to as the "synucleinopathies." The similarity of symptoms between DLB and Parkinson’s disease, and between DLB and Alzheimer’s disease, can often make it difficult for a doctor to make a definitive diagnosis. In addition, Lewy bodies are often also found in the brains of people with Parkinson's and Alzheimer’s diseases.  These findings suggest that either DLB is related to these other causes of dementia or that an individual can have both diseases at the same time.  DLB usually occurs sporadically, in people with no known family history of the disease. However, rare familial cases have occasionally been reported.

KEGG : 36 Lewy Body dementia (LDB) is neurodegenerative disease characterized by dementia, mild parkinsonism, and fluctuations in attention and alertness. It is the second most-common degenerative dementia after Alzheimer's disease. Progressive accumulation of alpha-synuclein- and ubiquitin-positive Lewy Bodies is seen in the brainstem, the limbic system or cortical and subcortical regions, depending on disease subtype. The genetic risk factors include alpha-synuclein mutations and SNCA locus triplicationslocus triplications. Mutations of leucine-rich repeat kinase 2 (LRRK2) and the glucocerebrosidase (GBA) gene have also been implicated in familial DLB.

UniProtKB/Swiss-Prot : 73 Dementia, Lewy body: A neurodegenerative disorder characterized by mental impairment leading to dementia, parkinsonism, fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Brainstem or cortical intraneuronal accumulations of aggregated proteins (Lewy bodies) are the only essential pathologic features. Patients may also have hippocampal and neocortical senile plaques, sometimes in sufficient number to fulfill the diagnostic criteria for Alzheimer disease.

Wikipedia : 74 Dementia with Lewy bodies (DLB) is a type of dementia accompanied by changes in behavior, cognition, and... more...

Related Diseases for Dementia, Lewy Body

Diseases related to Dementia, Lewy Body via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 340)
# Related Disease Score Top Affiliating Genes
1 parkinson disease 3, autosomal dominant 33.9 SNCAIP SNCA PRKN PARK7 MAPT LRRK2
2 perry syndrome 33.2 TH SNCA MAPT
3 parkinson disease 2, autosomal recessive juvenile 33.2 SNCA PRKN PARK7 LRRK2
5 tremor 31.7 SNCA PRKN MAPT LRRK2 GBA
6 sleep disorder 31.6 TH SNCA SLC6A3 MAPT
7 corticobasal degeneration 31.6 MAPT LRRK2 GBA
8 lrrk2 parkinson disease 31.4 SNCA PRKN LRRK2
9 essential tremor 31.3 SNCA SLC6A3 PRKN MAPT LRRK2 GBA
10 cerebral amyloid angiopathy, cst3-related 31.3 PRNP MAPT APP APOE
11 autonomic dysfunction 31.2 SNCA SLC18A2
12 gaucher's disease 31.2 SNCA PRKN GBA APOE
13 normal pressure hydrocephalus 31.2 MAPT APP APOE
14 hydrocephalus 31.2 SLC6A3 PRKN MAPT APP APOE
15 early-onset parkinson's disease 31.1 TH SNCA PRKN PARK7 LRRK2 GBA
16 leukoencephalopathy, hereditary diffuse, with spheroids 31.1 SNCA PRNP MAPT APP
17 psychotic disorder 31.1 TH SLC6A3 SLC18A2 MAOB CYP2D6 ACHE
18 apraxia 31.1 SLC6A3 MAPT APOE
19 pure autonomic failure 31.1 TH SNCA MAOB ACHE
20 cerebrovascular disease 31.1 MAPT APP APOE ACHE
21 posterior cortical atrophy 31.0 MAPT APOE
22 creutzfeldt-jakob disease 31.0 SNCA SLC6A3 PRNP PARK7 MAPT APP
23 genetic prion diseases 31.0 PRNP APOE
24 dysautonomia 31.0 SNCA PRNP GBA
25 binswanger's disease 31.0 MAPT APP APOE ACHE
26 mutism 31.0 SLC6A3 PRNP MAPT
27 simultanagnosia 31.0 MAPT APOE
28 alzheimer disease 2 31.0 MAPT BCHE APP APOE
29 mood disorder 31.0 TH SLC6A3 SLC18A2 MAOB
30 primary lateral sclerosis, adult, 1 30.9 SNCA MAPT
31 nervous system disease 30.9 SNCA PRNP MAPT APP APOE
32 fatal familial insomnia 30.9 PRNP MAPT APP
33 olivopontocerebellar atrophy 30.9 TH SNCA SLC6A3 MAPT
34 amnestic disorder 30.9 BCHE APP APOE ACHE
35 striatonigral degeneration 30.9 TH SNCA SLC6A3
36 huntington disease 30.9 TH SNCA SLC6A3 PRNP MAPT MAOB
37 prion disease 30.9 SNCA PRNP MAPT APP APOE
38 frontotemporal dementia 30.9 SNCB SNCA PRNP MAPT LRRK2 BCHE
39 personality disorder 30.9 TH SLC6A3 MAOB
40 ideomotor apraxia 30.9 MAPT BCHE
42 aceruloplasminemia 30.9 TH SNCA SLC6A3 PRNP PARK7 MAPT
43 neuroblastoma 30.9 TH SNCA PRNP PRKN MAPT CDK5
44 multiple system atrophy 1 30.9 TH SNCG SNCB SNCA SLC6A3 PRNP
45 anosognosia 30.9 BCHE APOE
46 amyloidosis 30.9 SNCA PRNP MAPT APP APOE
47 semantic dementia 30.9 MAPT APOE
48 restless legs syndrome 30.9 TH SNCA SLC6A3 PRKN MAPT MAOB
49 motor neuron disease 30.8 SNCA PRKN MAPT CYP2D6 APOE
50 vascular dementia 30.8 PRNP MAPT BCHE APP APOE ACHE

Graphical network of the top 20 diseases related to Dementia, Lewy Body:

Diseases related to Dementia, Lewy Body

Symptoms & Phenotypes for Dementia, Lewy Body

Human phenotypes related to Dementia, Lewy Body:

31 (show all 6)
# Description HPO Frequency HPO Source Accession
1 dementia 31 HP:0000726
2 visual hallucinations 31 HP:0002367
3 parkinsonism 31 HP:0001300
4 lewy bodies 31 HP:0100315
5 delusions 31 HP:0000746
6 fluctuations in consciousness 31 HP:0007159

Symptoms via clinical synopsis from OMIM:

Neurologic Central Nervous System:
visual hallucinations
fluctuations in consciousness
progressive dementia

Clinical features from OMIM:


UMLS symptoms related to Dementia, Lewy Body:

seizures, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness, hallucinations, visual

MGI Mouse Phenotypes related to Dementia, Lewy Body:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.41 ACHE APOE APP CDK5 GBA LRRK2
2 homeostasis/metabolism MP:0005376 10.41 ACHE APOE APP BCHE CDK5 GBA
3 cellular MP:0005384 10.34 APOE APP GBA LRRK2 MAOB MAPT
4 growth/size/body region MP:0005378 10.29 ACHE APOE APP GBA MAPT PARK7
5 mortality/aging MP:0010768 10.28 ACHE APOE APP BCHE CDK5 GBA
6 nervous system MP:0003631 10.25 ACHE APOE APP CDK5 GBA LRRK2
7 integument MP:0010771 10.17 APOE APP CDK5 GBA LRRK2 MAPT
8 no phenotypic analysis MP:0003012 10 ACHE APOE APP CDK5 LRRK2 MAPT
9 muscle MP:0005369 9.97 ACHE APOE APP MAPT PRKN PRNP
10 normal MP:0002873 9.9 APP CDK5 GBA LRRK2 MAPT PRKN
11 respiratory system MP:0005388 9.5 ACHE APOE CDK5 GBA LRRK2 PRKN
12 taste/olfaction MP:0005394 9.02 APOE MAPT SLC18A2 SLC6A3 SNCA

Drugs & Therapeutics for Dementia, Lewy Body

Drugs for Dementia, Lewy Body (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
Acetaminophen Approved Phase 4 103-90-2 1983
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
Prazosin Approved Phase 4 19216-56-9 4893
Iodine Approved, Investigational Phase 4 7553-56-2 807
Donepezil Approved Phase 4 120014-06-4 3152
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Memantine Approved, Investigational Phase 4 19982-08-2 4054
Corticosterone Experimental Phase 4 50-22-6 5753
11 Cytochrome P-450 CYP3A Inducers Phase 4
12 Central Nervous System Stimulants Phase 4
13 Tranquilizing Agents Phase 4
14 Antipsychotic Agents Phase 4
15 Psychotropic Drugs Phase 4
16 Central Nervous System Depressants Phase 4
17 Antidepressive Agents Phase 4
18 Quetiapine Fumarate Phase 4 111974-72-2
19 Narcotics Phase 4
20 Antipyretics Phase 4
21 Analgesics, Non-Narcotic Phase 4
22 Analgesics, Opioid Phase 4
23 Analgesics Phase 4
24 Narcotic Antagonists Phase 4
25 Antihypertensive Agents Phase 4
26 Adrenergic Antagonists Phase 4
27 Adrenergic alpha-Antagonists Phase 4
28 Adrenergic Agents Phase 4
29 Anti-Inflammatory Agents Phase 4
30 Fluorodeoxyglucose F18 Phase 4
31 Pharmaceutical Solutions Phase 4
32 Calamus Phase 4
33 cadexomer iodine Phase 4
34 Neurotransmitter Agents Phase 4
35 Nootropic Agents Phase 4
36 Cholinergic Agents Phase 4
37 Cholinesterase Inhibitors Phase 4
38 Dopamine Agents Phase 4
39 Antiparkinson Agents Phase 4
40 Excitatory Amino Acids Phase 4
41 Excitatory Amino Acid Antagonists Phase 4
Galantamine Approved Phase 3 357-70-0 9651
Pimavanserin Approved, Investigational Phase 3 706779-91-1 16058810
44 Sympathomimetics Phase 3
45 Autonomic Agents Phase 3
46 Serotonin 5-HT2 Receptor Antagonists Phase 3
47 Serotonin Agents Phase 3
48 Serotonin Antagonists Phase 3
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
Carvedilol Approved, Investigational Phase 2 72956-09-3 2585

Interventional clinical trials:

(show top 50) (show all 154)
# Name Status NCT ID Phase Drugs
1 Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable Sensors Unknown status NCT03098368 Phase 4 Rotigotine;Placebo
2 A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB) Completed NCT02345213 Phase 4 E2020;Placebo
3 A Randomised, Double-blind, Placebo-controlled, 6-month Study of the Efficacy and Safety of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies Completed NCT00855686 Phase 4 Memantine;Placebo
4 An Open Label, Single-Center Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies Completed NCT01023672 Phase 4 Armodafinil
5 Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) Completed NCT00043849 Phase 4 Quetiapine
6 Efficacy of Pain Treatment on Depression in Patients With Dementia. A Randomized Clinical Trial. Completed NCT02267057 Phase 4 Paracetamol;Buprenorphine;Paracetamol placebo;Buprenorphine placebo
7 Prazosin and CSF Biomarkers in mTBI Recruiting NCT03221751 Phase 4 prazosin hydrochloride;placebo
8 Longitudinal Imaging Biomarkers of Disease Progression in DLB Enrolling by invitation NCT03582488 Phase 4 18F-Flortaucipir
9 DaTSCAN Imaging in Aging and Neurodegenerative Disease Enrolling by invitation NCT01453127 Phase 4 I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)
10 Brain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
11 Monitoring Anti-Dementia Drugs by Serum Levels: Importance of Serum Levels, Drug-monitoring, Side-effects, Clinical Efficacy and Compliance (Translation of Official Danish Title) Not yet recruiting NCT04117178 Phase 4 Donepezil;Memantine
12 A Training and Fidelity Model to Move and Scale Evidence-based Dementia Care and Caregiver Support Programs Into Practice: The Case for COPE in PACE Service Settings Not yet recruiting NCT04165213 Phase 4
13 Donepezil as Add-On Treatment of Psychotic Symptoms in Patients With Dementia of the Alzheimer's Type Unknown status NCT00190021 Phase 3 donepezil
14 Evaluating the Effects of Music Interventions on Hospitalised People With Dementia Unknown status NCT00448318 Phase 2, Phase 3
15 A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase Completed NCT01278407 Phase 3 Donepezil 5 mg;Donepezil 10 mg;Donepezil matched placebo
16 GEHC Has Decided Not to Provide This Detail But Will Rely on the Brief Title Completed NCT00209456 Phase 3 DatSCAN
17 Oculomotor Recording in the Contribution to the Early Differential Diagnosis of Dementia With Lewy Bodies and Alzheimer's Disease Completed NCT01577394 Phase 3
18 An Open Label 24-Week, Flexible Dose Trial to Assess the Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies Completed NCT00230997 Phase 3 Galantamine
19 A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis Completed NCT03325556 Phase 3 Placebo;Pimavanserin 34 mg;Pimavanserin 20 mg
20 An Open Label, Multicenter Study, Evaluating the Safety and Efficacy of 18F-AV-133 PET Imaging to Identify Subjects With Dopaminergic Degeneration Among Subjects Presenting to a Movement Disorders Specialty Clinic With an Uncertain Diagnosis Completed NCT01550484 Phase 2, Phase 3 18F-AV-133
21 Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine Not yet recruiting NCT03858270 Phase 3 Memantine
22 A Long-Term Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB) Terminated NCT02928445 Phase 2, Phase 3 RVT-101 35 mg;RVT-101 70 mg
23 A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies Completed NCT00598650 Phase 2 E2020
24 A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB) Completed NCT02669433 Phase 2 RVT-101 35 mg;RVT-101 70 mg;Placebo
25 Detection of Striatal Dopaminergic Degeneration and Neocortical Amyloid Pathology in Patients With Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease, and Healthy Elderly Volunteers Completed NCT01503944 Phase 1, Phase 2 18F-AV-133;18F-AV-45
26 A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia Completed NCT02910102 Phase 2 RVT-101 35 mg;Placebo
27 A Phase 2, Double-blind, Randomized, Placebo-controlled Cross-over Study of Nelotanserin Versus Placebo in Lewy Body Dementia (LBD) Subjects Experiencing Visual Hallucinations (VH) Completed NCT02640729 Phase 2 Nelotanserin;Placebo
28 Imaging Inflammation in Patients With Diffuse Lewy Body Disease Completed NCT02702102 Phase 2 11C-PBR28
29 Double-blind Study of E2020 in Patients With Dementia With Lewy Bodies - Phase II Completed NCT00543855 Phase 2 3 mg Donepezil hydrochloride;5 mg Donepezil hydrochloride;10 mg Donepezil hydrochloride;Placebo
30 A Double-blind, Placebo-controlled Multicentre Trial of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies Completed NCT00630500 Phase 2 Memantine;Placebo
31 A Phase 2, Double-blind, Randomized, Placebo-controlled Study of Nelotanserin Versus Placebo in Subjects With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) Who Have REM Sleep Behavior Disorder (RBD) Completed NCT02708186 Phase 2 Nelotanserin;Placebo
32 A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies Recruiting NCT03467152 Phase 2 E2027;Placebo
33 Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB) Recruiting NCT03305809 Phase 2 LY3154207;Placebo
34 A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies (DLB) Recruiting NCT04001517 Phase 2 Neflamapimod
35 A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies (DLB) Recruiting NCT03888222 Phase 2 Placebo Oral Tablet;Bosutinib Oral Tablet
36 A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Nilotinib Treatment on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies (DLB) Recruiting NCT04002674 Phase 2 Placebo oral capsule;Nilotinib Oral Capsule
37 A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of K0706 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics and Clinical Outcomes in Dementia With Lewy Bodies (DLB) Recruiting NCT03996460 Phase 2 Placebo oral capsule;96 mg of K0706;192 mg K0706
38 Safety and Diagnostic Performance of 11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes Recruiting NCT03555292 Phase 2 11C-PiB
39 The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease Recruiting NCT03775096 Phase 2 Carvedilol
40 Ambroxol as a Novel Disease Modifying Treatment for Parkinson's Disease Dementia Recruiting NCT02914366 Phase 2 Ambroxol
41 A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of DA-9805 in Subjects With Parkinson's Disease Active, not recruiting NCT03189563 Phase 2 DA-9805 45mg;DA-9805 90mg
42 A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib (Tasigna®) on Safety, Biomarkers and Clinical Outcomes in Subjects With Mild to Moderate Alzheimer's Disease Active, not recruiting NCT02947893 Phase 2 Placebo Capsule(s) Once a Day by Mouth;Nilotinib Capsule(s) Once a Day by Mouth
43 Effect of Donepezil on Cognition in Parkinson's Disease With Mild Cognitive Impairment (PD-MCI) Active, not recruiting NCT02450786 Phase 2 Donepezil
44 A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease Active, not recruiting NCT02954978 Phase 2 Placebo Oral Capsule;Nilotinib 150mg oral capsule [Tasigna];Nilotinib 300mg oral capsule [Tasigna]
45 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of NA-831 in Alzheimer Patients With Mild Cognitive Impairment Not yet recruiting NCT03538522 Phase 2 N-831(Traneurocin) 10 mg QD;NA-831 (Traneurocin) 20 mg QD;NA-831 (Traneurocin) 40 mg QD;Placebo oral capsule QD
46 An Open-label Study of Nelotanserin in Patients With Lewy Body Dementia Who Have Frequent Visual Hallucinations or REM Sleep Behavior Disorder Terminated NCT02871427 Phase 2 Nelotanserin
47 A Randomized, Double-blind, Placebo Controlled, Dose Ranging Study to Assess the Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies Withdrawn NCT03592862 Phase 2 HTL0018318;Placebo
48 An Open-Label, Single-Dose Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Subjects Completed NCT04023877 Phase 1 E2027
49 An Open-Label Trial of Donepezil in Fragile X Syndrome Completed NCT00220584 Phase 1 donepezil
50 Open Label Dose Escalation of Nilotinib in Cognitively Impaired Parkinson Disease Patients With Elevated Cerebrospinal Fluid and Blood α-Synuclein Completed NCT02281474 Phase 1 Nilotinib

Search NIH Clinical Center for Dementia, Lewy Body

Cochrane evidence based reviews: lewy body disease

Genetic Tests for Dementia, Lewy Body

Genetic tests related to Dementia, Lewy Body:

# Genetic test Affiliating Genes
1 Lewy Body Dementia 29 GBA SNCA SNCB
2 Lewy Bodies 29

Anatomical Context for Dementia, Lewy Body

MalaCards organs/tissues related to Dementia, Lewy Body:

Brain, Testes, Heart, Eye, Colon, Skin, T Cells

Publications for Dementia, Lewy Body

Articles related to Dementia, Lewy Body:

(show top 50) (show all 951)
# Title Authors PMID Year
The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. 54 61 56 6
14755719 2004
Prominent psychiatric symptoms and glucose hypometabolism in a family with a SNCA duplication. 56 6
18852445 2008
Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. 56 6
18332251 2008
Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia. 56 6
18195271 2008
Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. 56 6
16358335 2006
Beta-synuclein gene alterations in dementia with Lewy bodies. 56 6
15365127 2004
Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease. 54 56
18335262 2008
Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. 54 56
18413475 2008
A novel PSEN2 mutation associated with a peculiar phenotype. 61 56
18427071 2008
Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies. 56
29743672 2018
The L444P GBA mutation is associated with early-onset Parkinson's disease in Mexican Mestizos. 6
23448517 2013
A germline or de novo mutation in two families with Gaucher disease: implications for recessive disorders. 6
22713811 2013
Gaucher disease: frequency of the N370S mutation in the Greek population. 6
20662857 2010
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. 6
19286695 2009
Re: Alpha-synuclein gene duplication is present in sporadic Parkinson disease. 6
18852448 2008
Re: Alpha-synuclein gene duplication is present in sporadic Parkinson disease. 6
18852449 2008
The need for appropriate genotyping strategies for glucocerebrosidase mutations in cohorts with Parkinson disease. 6
18541817 2008
alpha-Synuclein gene duplication is present in sporadic Parkinson disease. 6
17625105 2008
LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. 6
18022370 2007
Glucocerebrosidase mutations and risk of Parkinson disease in Chinese patients. 6
17620502 2007
Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. 6
17251522 2007
Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. 56
16790605 2006
Lrrk2 and Lewy body disease. 56
16437559 2006
Biochemical and pathological characterization of Lrrk2. 56
16437584 2006
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. 56
16237129 2005
A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer's disease. 56
15732120 2005
The E46K mutation in alpha-synuclein increases amyloid fibril formation. 6
15632170 2005
Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. 6
15498564 2004
Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. 6
15451224 2004
Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. 6
15451225 2004
Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. 6
14755720 2004
alpha-Synuclein locus triplication causes Parkinson's disease. 6
14593171 2003
Dementia with Lewy bodies: disease concept and genetics. 56
12898286 2003
A patient with dementia with Lewy bodies and codon 232 mutation of PRNP. 56
12451207 2002
Familial diffuse Lewy body disease, eye movement abnormalities, and distribution of pathology. 56
11890854 2002
[Diagnostic criteria of diffuse Lewy body disease]. 56
11068444 2000
Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. 6
10796875 2000
Familial dementia with Lewy bodies (DLB). 56
10505432 1999
Autosomal dominant diffuse Lewy body disease. 56
9705138 1998
Molecular analysis and clinical findings in the Spanish Gaucher disease population: putative haplotype of the N370S ancestral chromosome. 6
9554746 1998
Familial parkinsonism, dementia, and Lewy body disease: study of family G. 56
9382476 1997
Clinical features of familial diffuse Lewy body disease. 56
9276199 1997
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. 56
8909416 1996
Characteristics of gene mutations among 32 unrelated Japanese Gaucher disease patients: absence of the common Jewish 84GG and 1226G mutations. 6
7789963 1995
The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. 56
7818242 1995
The apolipoprotein E allele epsilon 4 is overrepresented in patients with the Lewy body variant of Alzheimer's disease. 56
7936253 1994
Gaucher disease as a paradigm of current issues regarding single gene mutations of humans. 6
8516282 1993
Gaucher's disease in the United Kingdom: screening non-Jewish patients for the two common mutations. 6
8487270 1993
Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease. 6
8450045 1993
Diffuse Lewy body disease presenting with supranuclear gaze palsy, parkinsonism, and dementia: a case report. 56
1484531 1992

Variations for Dementia, Lewy Body

ClinVar genetic disease variations for Dementia, Lewy Body:

6 (show all 16) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 GBA NM_000157.4(GBA):c.887G>A (p.Arg296Gln)SNV Pathogenic 4328 rs78973108 1:155207244-155207244 1:155237453-155237453
2 SNCB NM_003085.5(SNCB):c.208G>A (p.Val70Met)SNV Pathogenic 7025 rs104893936 5:176053473-176053473 5:176626472-176626472
3 SNCB NM_003085.5(SNCB):c.368C>A (p.Pro123His)SNV Pathogenic 7026 rs104893937 5:176048219-176048219 5:176621218-176621218
4 SNCA NM_000345.4(SNCA):c.157G>A (p.Ala53Thr)SNV Pathogenic 14007 rs104893877 4:90749300-90749300 4:89828149-89828149
5 SNCA NM_000345.4(SNCA):c.136G>A (p.Glu46Lys)SNV Pathogenic 14010 rs104893875 4:90749321-90749321 4:89828170-89828170
6 SNCA SNCA, DUPLICATIONduplication Pathogenic 14011
7 GBA NM_000157.4(GBA):c.115+1G>ASNV Pathogenic 93445 rs104886460 1:155210420-155210420 1:155240629-155240629
8 SNCA NC_000004.11:g.(?_90647315)_(90756828_?)dupduplication Pathogenic 639372 4:90647315-90756828 4:89726164-89835677
9 SNCA NC_000004.11:g.(?_90647315)_(90756838_?)dupduplication Pathogenic 531846 4:90647315-90756838 4:89726164-89835687
10 GBA NM_000157.4(GBA):c.1297G>T (p.Val433Leu)SNV Pathogenic 4292 rs80356769 1:155205563-155205563 1:155235772-155235772
11 GBA NM_000157.4(GBA):c.1604G>A (p.Arg535His)SNV Pathogenic 4311 rs75822236 1:155204793-155204793 1:155235002-155235002
12 GBA NM_000157.4(GBA):c.1504C>T (p.Arg502Cys)SNV Pathogenic 4295 rs80356771 1:155204987-155204987 1:155235196-155235196
13 GBA NM_000157.4(GBA):c.1342G>C (p.Asp448His)SNV Pathogenic 4293 rs1064651 1:155205518-155205518 1:155235727-155235727
14 GBA NM_000157.4(GBA):c.1448T>C (p.Leu483Pro)SNV risk factor 4288 rs421016 1:155205043-155205043 1:155235252-155235252
15 GBA NM_000157.4(GBA):c.1226A>G (p.Asn409Ser)SNV Conflicting interpretations of pathogenicity 4290 rs76763715 1:155205634-155205634 1:155235843-155235843
16 SNCA NM_000345.4(SNCA):c.349C>A (p.Pro117Thr)SNV Uncertain significance 652694 4:90650386-90650386 4:89729235-89729235

UniProtKB/Swiss-Prot genetic disease variations for Dementia, Lewy Body:

# Symbol AA change Variation ID SNP ID
1 SNCA p.Glu46Lys VAR_022703 rs104893875

Expression for Dementia, Lewy Body

Search GEO for disease gene expression data for Dementia, Lewy Body.

Pathways for Dementia, Lewy Body

Pathways related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
5 11.84 SLC18A2 MAOB CYP2D6 APP
Show member pathways
Show member pathways
11.77 TH SLC18A2 CDK5
10 11.44 PRNP MAPT APP
Show member pathways
11.33 TH SLC6A3 ACHE
13 11.24 CYP2D6 APOE ACHE
14 11.11 TH SLC6A3 SLC18A2
Show member pathways
Show member pathways
10.98 TH SLC6A3 SLC18A2 MAOB
18 10.72 TH MAOB
19 10.65 TH ACHE

GO Terms for Dementia, Lewy Body

Cellular components related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.43 TH SNCG SNCB SNCAIP SNCA SLC6A3
2 mitochondrion GO:0005739 10.18 TH SNCA PRKN PARK7 MAPT MAOB
3 endoplasmic reticulum GO:0005783 10.17 PRNP PRKN PARK7 LRRK2 GBA CYP2D6
4 Golgi apparatus GO:0005794 10.14 SNCA PRNP PRKN LRRK2 GBA APP
5 cell GO:0005623 10.07 TH SNCA PRNP PRKN PARK7 MAPT
6 perinuclear region of cytoplasm GO:0048471 10.06 SNCG SNCA PRKN PARK7 APP ACHE
7 synapse GO:0045202 10.04 SNCG SNCB SNCA LRRK2 CDK5 APP
8 dendrite GO:0030425 9.99 TH PRNP MAPT LRRK2 CDK5 APOE
9 presynapse GO:0098793 9.88 SNCB SNCA PRKN PARK7 CDK5
10 membrane raft GO:0045121 9.88 SLC6A3 PRNP PARK7 MAPT LRRK2 APP
11 perikaryon GO:0043204 9.85 TH LRRK2 CDK5 APP
12 growth cone GO:0030426 9.85 SNCA MAPT LRRK2 CDK5 APP
13 postsynapse GO:0098794 9.83 SNCA PRNP LRRK2 CDK5
14 synaptic vesicle membrane GO:0030672 9.79 SNCA SLC18A2 LRRK2
15 neuromuscular junction GO:0031594 9.78 CDK5 APP ACHE
16 neuron projection GO:0043005 9.76 TH SLC6A3 PRKN PARK7 MAPT LRRK2
17 terminal bouton GO:0043195 9.73 TH SNCA SLC18A2 LRRK2
18 synaptic vesicle GO:0008021 9.73 TH SNCAIP SNCA SLC18A2 LRRK2 APP
19 synaptic cleft GO:0043083 9.62 APOE ACHE
20 dopaminergic synapse GO:0098691 9.62 SLC6A3 SLC18A2
21 inclusion body GO:0016234 9.62 SNCB SNCA PRNP LRRK2
22 neuronal cell body GO:0043025 9.61 TH SNCG SNCAIP SNCA SLC6A3 MAPT
23 nuclear envelope lumen GO:0005641 9.6 BCHE APP
24 main axon GO:0044304 9.59 MAPT APP
25 axon GO:0030424 9.28 TH SNCG SNCA SLC6A3 PARK7 MAPT

Biological processes related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 10.05 TH SNCA SLC6A3 MAOB BCHE
2 negative regulation of gene expression GO:0010629 10.03 PRKN PARK7 MAPT APP APOE
3 chemical synaptic transmission GO:0007268 10.02 SNCG SNCB SNCA SLC18A2 CDK5
4 cellular protein metabolic process GO:0044267 10 SNCAIP SNCA PRKN APP APOE
5 autophagy GO:0006914 9.98 PRKN PARK7 LRRK2 GBA
6 negative regulation of neuron apoptotic process GO:0043524 9.96 SNCB SNCA PRKN PARK7 APOE
7 neuron projection development GO:0031175 9.95 MAPT GBA CDK5 APP APOE
8 cellular response to oxidative stress GO:0034599 9.92 SNCA PARK7 LRRK2
9 response to oxidative stress GO:0006979 9.92 PRNP PRKN LRRK2 APP APOE
10 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.91 SNCA PARK7 APP
11 cholesterol metabolic process GO:0008203 9.91 GBA CYP2D6 APP APOE
12 positive regulation of proteasomal ubiquitin-dependent protein catabolic process GO:0032436 9.89 PRKN LRRK2 GBA
13 regulation of autophagy GO:0010506 9.89 PRKN MAPT LRRK2
14 positive regulation of protein binding GO:0032092 9.89 PRKN LRRK2 CDK5 APP
15 mitochondrion organization GO:0007005 9.89 PRKN PARK7 LRRK2 GBA CDK5
16 excitatory postsynaptic potential GO:0060079 9.88 SNCA LRRK2 CDK5
17 learning GO:0007612 9.88 TH PRKN BCHE APP
18 locomotory behavior GO:0007626 9.88 TH SLC6A3 SLC18A2 PRKN APP
19 protein destabilization GO:0031648 9.85 SNCA PRNP PRKN
20 cellular response to amyloid-beta GO:1904646 9.85 PRNP CDK5 APP
21 synaptic vesicle endocytosis GO:0048488 9.85 SNCB SNCA CDK5
22 negative regulation of protein phosphorylation GO:0001933 9.85 SNCA PRNP PRKN PARK7 LRRK2
23 response to cocaine GO:0042220 9.83 SNCA SLC6A3 CDK5
24 regulation of dopamine secretion GO:0014059 9.81 SNCG SNCA PRKN
25 positive regulation of neuron death GO:1901216 9.81 SNCA PRNP MAPT CDK5
26 microglial cell activation GO:0001774 9.8 SNCA MAPT APP
27 cellular response to copper ion GO:0071280 9.8 SNCA PRNP APP
28 adult locomotory behavior GO:0008344 9.8 SNCG SNCA PRKN PARK7 APP
29 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.77 PRKN PARK7 LRRK2
30 negative regulation of reactive oxygen species biosynthetic process GO:1903427 9.75 SLC18A2 PARK7
31 cellular response to dopamine GO:1903351 9.75 PRKN LRRK2
32 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.75 PARK7 LRRK2
33 neurotransmitter biosynthetic process GO:0042136 9.75 TH SLC6A3 ACHE
34 negative regulation of protein processing GO:0010955 9.74 PRNP LRRK2
35 central nervous system neuron development GO:0021954 9.74 MAPT CDK5
36 cellular copper ion homeostasis GO:0006878 9.74 PRNP APP
37 negative regulation of amyloid-beta formation GO:1902430 9.74 PRNP APOE
38 supramolecular fiber organization GO:0097435 9.74 SNCA MAPT
39 negative regulation of long-term synaptic potentiation GO:1900272 9.74 PRNP APP APOE
40 amyloid fibril formation GO:1990000 9.73 MAPT APP
41 locomotory exploration behavior GO:0035641 9.73 LRRK2 APOE
42 regulation of protein metabolic process GO:0051246 9.73 GBA APOE
43 amyloid precursor protein metabolic process GO:0042982 9.73 APOE ACHE
44 neuron projection maintenance GO:1990535 9.73 PRNP APP
45 negative regulation of oxidative stress-induced cell death GO:1903202 9.73 PRKN PARK7
46 regulation of neurotransmitter secretion GO:0046928 9.73 SNCG SNCAIP SNCA PRKN
47 positive regulation of protein metabolic process GO:0051247 9.72 GBA APP
48 neurotransmitter catabolic process GO:0042135 9.72 MAOB ACHE
49 regulation of dopamine metabolic process GO:0042053 9.72 SLC6A3 PRKN
50 synapse organization GO:0050808 9.72 SNCG SNCB SNCA MAPT APP

Molecular functions related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 10.03 PARK7 MAPT MAOB LRRK2 APOE ACHE
2 signaling receptor binding GO:0005102 9.91 SLC6A3 PARK7 GBA APP APOE
3 protein-containing complex binding GO:0044877 9.85 SLC6A3 PRNP PRKN PARK7 APOE
4 microtubule binding GO:0008017 9.77 SNCA PRNP MAPT LRRK2 CDK5
5 chaperone binding GO:0051087 9.75 PRNP PRKN MAPT
6 copper ion binding GO:0005507 9.7 SNCA PRNP PARK7
7 enzyme binding GO:0019899 9.7 TH SNCA PRKN PARK7 MAPT BCHE
8 identical protein binding GO:0042802 9.7 SNCAIP SNCA PRNP PRKN PARK7 MAPT
9 tau protein binding GO:0048156 9.67 SNCA CDK5 APOE
10 amyloid-beta binding GO:0001540 9.62 PRNP BCHE APOE ACHE
11 dopamine binding GO:0035240 9.57 TH SLC6A3
12 tubulin binding GO:0015631 9.56 PRNP PRKN MAPT LRRK2
13 lipoprotein particle binding GO:0071813 9.55 MAPT APOE
14 monoamine transmembrane transporter activity GO:0008504 9.54 SLC6A3 SLC18A2
15 cupric ion binding GO:1903135 9.48 PRNP PARK7
16 cholinesterase activity GO:0004104 9.43 BCHE ACHE
17 acetylcholinesterase activity GO:0003990 9.4 BCHE ACHE
18 cuprous ion binding GO:1903136 8.92 SNCB SNCA PRNP PARK7

Sources for Dementia, Lewy Body

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....